InvestorsHub Logo
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: None

Saturday, 12/15/2012 11:07:20 AM

Saturday, December 15, 2012 11:07:20 AM

Post# of 80490
I'm sure Scott Matusow will clarify sales of Icluelis...

I think Rachel Minn's question at 36:15 is key. Essentially she highlights the data for T315i patients as less heavily pre-treated and Frank confirms these patients have much fewer AE's. This suggests front-line use will have more favorable safety profile.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.